No profile data available.
Pulmatrix, Inc. (PULM) is a healthcare company in the additional infection treatment pharmaceuticals industry, based in Framingham, United States, with about 2 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$5.16 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $5.33 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States.
Pulmatrix reported $0 in revenue for fiscal year 2025, down 100.0% from $7.81 million in fiscal year 2024. In Q1 2026 revenue was $0.
$5.33 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional infection treatment pharmaceuticals) include Tarsus Pharmaceuticals, Inc. (TARS), Scynexis, Inc. (SCYX), Daré Bioscience, Inc. (DARE), 60 Degrees Pharmaceuticals, Inc. (SXTP).